Cambridge Investment Research Advisors
CORT icon

Cambridge Investment Research Advisors’s Corcept Therapeutics CORT Stock Holding History

Cambridge Investment Research Advisors’s Portfolio CORT Stock Details CORT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.06M Sell
35,157
-7,597
-18% -$459K 0.01% 1366
2026
Q1 		$1.72M Buy
42,754
+9,009
+27% +$337K ﹤0.01% 1716
2025
Q4 		$1.17M Buy
33,745
+18,802
+126% +$1.48M ﹤0.01% 1974
2025
Q3 		$1.24M Buy
14,943
+4,671
+45% +$338K ﹤0.01% 1883
2025
Q2 		$754K Sell
10,272
-1,733
-14% -$126K ﹤0.01% 2175
2025
Q1 		$1.37M Sell
12,005
-7,761
-39% -$472K ﹤0.01% 1620
2024
Q4 		$996K Sell
19,766
-7,089
-26% -$371K ﹤0.01% 1878
2024
Q3 		$1.24M Sell
26,855
-259,395
-91% -$9.22M ﹤0.01% 1705
2024
Q2 		$9.3M Sell
286,250
-38,021
-12% -$1.04M 0.03% 497
2024
Q1 		$8.17M Buy
324,271
+313,543
+2,923% +$7.41M 0.03% 531
2023
Q4 		$348K Sell
10,728
-162,724
-94% -$4.47M ﹤0.01% 2485
2023
Q3 		$4.73M Buy
+173,452
New +$5.02M 0.02% 680
2023
Q2 		– Sell
-366,220
Closed -$7.93M – 3193
2023
Q1 		$7.93M Buy
+366,220
New +$8.03M 0.04% 440

Other funds holding CORT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ISL
Ingalls & Snyder LLC New York $3.66B AUM 57.76% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PA
Parallel Advisors San Francisco, California $6.56B AUM 32.24% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Cambridge Investment Research Advisors's CORT Position: Q2 2026 in Review

Cambridge Investment Research Advisors reduced its Corcept Therapeutics (CORT) stake by 18% in Q2 2026, selling an estimated $459K and leaving 35,157 shares worth $3.06M. The position accounts for 0.01% of the portfolio, ranked #1366.

Cambridge Investment Research Advisors first reported a position in CORT in Q1 2023 and has held it in 13 quarters since. The position peaked at $9.3M in Q2 2024. 423 funds tracked by Wall St. Rank hold CORT as of Q2 2026.

  • Cambridge Investment Research Advisors held 35,157 shares of Corcept Therapeutics worth $3.06M as of Q2 2026.
  • Cambridge Investment Research Advisors sold 7,597 Corcept Therapeutics shares in Q2 2026, an estimated $459K.
  • Corcept Therapeutics made up 0.01% of Cambridge Investment Research Advisors's portfolio in Q2 2026, its #1366 holding.
  • Cambridge Investment Research Advisors first reported a position in Corcept Therapeutics in Q1 2023 and has held it in 13 quarters since.
  • Cambridge Investment Research Advisors's Corcept Therapeutics position peaked at $9.3M in Q2 2024.
  • 423 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q2 2026.

Based on Cambridge Investment Research Advisors's 13F filing for Q2 2026, filed 27 Jul 2026.